SABCS: Extending tamoxifen to 10 years beneficial in breast CA
(HealthDay)—For women with estrogen receptor (ER)-positive early breast cancer, continuing tamoxifen to 10 years correlates with reduced risk of recurrence and lower breast cancer-specific and overall mortality, according ...
Dec 5, 2012
0
0